Long-term follow-up of beryllium sensitized workers from a single employer

BMC Public Health

Table 3 Descriptive characteristics and clinical evaluation results of participants with clinical Chronic Beryllium Disease at follow-up

Parameter	Pt.1	Pt.2	Pt. 3	Pt.4	Pt 5	Pt 6	Pt.7	Pt.8
Baseline diagnosis	CBD	CBD	CBD	CBD	CBD	CBD	CBD	BeS
Baseline to current evaluation, in yrs.	12	5	12	4	1	9	11	7
Yrs. since first worked at site to initial evaluation	4	10	23	1	26	22	8	18
Yrs. of beryllium exposure	15	12	29	2	27	36	10	25
Yrs. since last worked at site	6	3	6	3	0	9	10	0
Smoking Status	Never smoker	Never smoker	Ex smoker	Ex smoker	Ex smoker	Ex smoker	Ex smoker	Current smoker
No. of pack years	0	0	9	20	11	71	8	21.5
Steroid Use	No	Yes (Inhalational)	No	Yes (Inhalational)	No	Yes (Inhalational)	Yes (oral)	No
BeLPT result (Lab 1/Lab 2)	+/+	+/-	+/-	+/+	+/+	-/-	+/-	+/+
Pulmonary Function tests (% predicted)
FEV₁
Initial	73	87	81	85	65	95	72	87
Final	62	93	79	89	63	85	70	71
FVC
Initial	80	78	82	97	71	121	83	89
Final	62	87	82	96	69	89	79	68
FEV₁/FVC
Initial	92	111	100	88	92	78	87	97
Final	99	107	98	92	89	94	88	106
TLC
Initial	88	78	97	107	95	96	95	88
Final	80	58	88	91	87	89	N/A	79
D_LCO
Initial	108	95	124	98	N/A	97	131	116
Final	49	69	56	64	53	62	N/A	82
X-ray Changes or CBD	Bilateral hilar adenopathy and diffuse small opacities	None	None	None	None	Borderline enlargement of lymph nodes	None	None
Basis for Clinical CBD	X-ray, Low D_LCO, Low FVC	Low TLC, Low D_LCO	Low D_LCO	Low D_LCO	Low FVC, Low D_LCO	X-ray, Low D_LCO	On oral steroids for presumed clinical CBD	Low FVC, Low TLC

ISSN: 1471-2458